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Balloon Treatment Test DCB Control DCB POBA
ANOVA
P-value
EEL Area (mm2) 2.871.29 3.051.08 2.590.79 0.58
IEL Area (mm2) 1.680.94 1.840.80 1.650.56 0.81
Neointimal area
(mm2)
0.110.08 0.310.27 0.120.18 0.03
% Stenosis 7.385.20 16.9113.08 8.9212.70 0.09
Mean PGs/
Collagen Score
(Media)
1.170.72 2.070.65 0.790.81 0.0007
Medial SMC Loss
Score (Circumference)
1.130.74 1.940.60 0.630.83 0.0007
Mean Fibrin (Intima/
Media) Score
0.880.91 1.610.79 0.0420.14 <0.0001
Mean Inﬂammation
(Intima/Media) Score
0.710.66 1.190.39 0.330.89 0.003
Abbreviations: EEL¼external elastic lamina, IEL¼internal elastic lamina, PG¼proteoglycan,
SMC¼smooth muscle cell
% Stenosis deﬁned as [1-(lumen area/IEL area)]*100
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Background: In the DES era, the best strategy to treat 001 bifurcated lesions remains
unanswered. This is the ﬁrst prospective registry assessing the efﬁcacy and safety of
second generation of drug-eluting balloon (DEB) (EurocorGm), (3.0mg/m2 balloon
surface area), in patients with 001 bifurcated lesions placed in secondary branches
Methods: After 2.7 years, 51 patients with 001 bifurcated lesion and clinical evidence
of myocardial ischemia related to the target lesion were prospectively included in this
multicenter (8 centers) registry. After optimal dilatation, a PEB was inﬂated for a
minimum of 45 seconds. Left main bifurcated lesions, severe calciﬁcation and cardio-
genic shock, were the only exclusion criteria. In 2 eligible patients after regular balloon
pre-dilatation the DEB could not be used and patients were excluded of the registry.
Results: Patients were 6212 years old, 42% diabetic, 56% ACS as clinical pre-
sentation. The most frequent lesion treated was ﬁrst diagonal (41%). Radial approach
was done in most cases (84%). Pre-dilatation was done in all the cases, with cutting
balloon in 59%. Angiographic success was 90% (by protocol in 10% of lesions a BMS
was implanted because of signiﬁcant acute recoil (3) or coronary dissection more that
type B (2)). At 1 month (follow-up completed in all the patients) there was no adverse
event (MACE). At a mean of 11.2  2.2 months (12 months completed in 81% of
patients) there was 14.2% cumulative non-hierarchical MACE (1 MI, 0 cardiac deaths,
7 TLR). There was no thrombosis or occlusion. In 4 selected centers at a mean of 7.2
 1.1 months, angiographic follow-up was completed in 31/36 (86%) patients;
reference diameter was 2.2  0.3 mm with a binary restenosis of (6) 19.3%.
Conclusions: We report the ﬁrst registry assessing 001 bifurcated lesion placed in
small vessels (2.2mm). This is a rare type of coronary lesion (inclusion period of 2.7
years) that was observed in a relative young and diabetic population. In this complex
setting, second generation of PEB is a safe strategy, technically easier and it seems to
be effective at mid-term follow up with a 14% MACE at 1 year.
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Background: Scoring balloons are useful in the acute treatment of in-stent restenosis,
ﬁbro-calciﬁc and bifurcation lesions but have not been shown to affect the restenosis
rate as compared to conventional balloons. A novel paclitaxel-coated scoring balloon
(SB) was developed to overcome these limitations. Prior studies in a coronary swine
model demonstrated a marked reduction in restenosis using these SB and no evidence
of local or systemic adverse effects.
Methods: SB were coated with paclitaxel admixed with a speciﬁc excipient. Patients
at 5 sites (4 in Germany and one in Brazil) with bare metal stent in-stent restenosis
(ISR) were randomized 1:1 to treatment with either a drug-coated or bare SB. Baseline
and 6-month follow-up quantitative coronary angiography was performed by an in-
dependent blinded core lab and all patients were evaluated clinically at 30 days, 6 and
12 months. The primary endpoint was angiographic in-segment late lumen loss (LLL).
Secondary endpoints included clinically driven target lesion revascularization (TLR),
major adverse cardiovascular events (MACE), stent thrombosis (ST) and other clinical
and angiographic variables. Patients will be followed clinically for 2 years.
Results: A total of 61 patients were randomized (28 uncoated and 33 coated SB);
mean age 63.3 yrs, males 72%, and presence of diabetes 38%. At 6-month angiog-
raphy, late lumen loss in-segment was 0.480.51 mm in the uncoated SB group
versus 0.090.43 mm in the drug-coated SB group (p¼0.002; ITT analysis). The rate
of binary restenosis was 41% in the uncoated SB group versus 6.5% in the drug-
coated SB group (p< 0.05). At one year, the MACE rate was 32% with the uncoated
SB vs. 6.7% with the drug-coated SB (p< 0.05).
Conclusions: A novel paclitaxel-coated coronary SB has been developed and ach-
ieved successful results in a ﬁrst-in-human randomized controlled trial [ClinicalTrials.
gov Identiﬁer: NCT01495533].B80 JACC Vol 64/11/Suppl B j September 13–17,TCT-276
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Background: Drug-coated balloons (DCB) rapidly transfer antirestenotic drug along
the arterial vessel wall without a metallic implant. DCBs, coated with a mixture of
paclitaxel and an excipient (to modulate drug release), may have clinical application in
treating coronary in -stent restenosis and in peripheral arterial stenoses. This study
characterizes the in vivo elution of paclitaxel and vascular compatibility of the novel
Agent Paclitaxel-coated PTCA balloon for coronary vasculature.
Methods: The Agent DCB TransPAX coating consists of 80% Paclitaxel/20%
excipient (2ug/mm2 dose density [Boston Scientiﬁc Corporation, Natick MA], “test
DCB”). Controls included a commercially available paclitaxel-coated balloon (3ug/
mm2, Pantera Lux [Biotronik AG, Switzerland] “control DCB”) and an uncoated
balloon (“POBA”). Balloons were inﬂated distal to a marker stent (BMS) or a BMS
was implanted prior balloon inﬂation in the same position. The level of paclitaxel was
measured at time points through 28d and vascular response was analyzed 28d post
implantation.
Results: The level of paclitaxel in the coronary arteries was equivalent between test
DCB and control DCB (reaching 50% of initial levels between 7 and 14d). Vessel
areas were similar and endothelialization of luminal surfaces was nearly complete in
all groups by 28d. Neointimal area was similar between test DCB and POBA; both
were statistically less than control DCB. Medial smooth muscle cell loss and
inﬂammation were greatest in control DCB vessels compared to test DCB vessels
followed by POBA. Similarly, mean ﬁbrin score (intima/media) was highest in the
control DCB, followed by test DCB vessels and then POBA vessels (See table).Conclusions: These results show the Agent DCB results in equivalent tissue levels
with less nominal drug than the control DCB and support the safety of the Agent DCB
in porcine coronary arteries.
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Background: Limited data are available as to whether the combination of drug coated
balloons (DCB) plus drug eluting stents (DES) would be more efﬁcacious than DES in
lesions or patients at high risk for restenosis. A combination of paclitaxel (present in
coated balloons) and a limus drug may exert a synergistic effect in preventing target
lesion revascularization (TLR).
Methods: Between 2009 and 2013, 68 patients (82 lesions) were treated with a
combination of DCB and implantation of a second-generation DES. These were
compared to 513 lesions treated with conventional second-generation DES in the same
period. Primary endpoint was TLR at 1- and 2-years of follow-up.
Results: The DCB plus DES group had more in-stent restenosis (ISR); 42.3% vs.
9.5%, p < 0.001 and higher prevalence of diabetes mellitus (DM); 36.4% vs. 22.2%,
p ¼ 0.007 compared to the DES group. After propensity matching, there were no2014 j TCT Abstracts/Drug-Eluting Balloons and Local Drug Delivery
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMsigniﬁcant differences in the 77 matched pairs. Stent proﬁles were also similar in both
groups. Kaplan–Meier analysis (Figure) demonstrated no signiﬁcant differences in 1-
year (5% vs. 2.5%, p ¼ 0.59) or 2-year (20.7% vs. 11.5%, p ¼ 0.25) TLR between the
two groups.Conclusions: In our study, no additional beneﬁt of DCB plus DES combination was
found when compared to conventional DES implantation. However, a large ran-
domized study is essential to evaluate the efﬁcacy of DCB plus DES combination.
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Background: Recently, paclitaxel-coated balloon (PCB) has emerged as a potential
alternative to the current treatment of in-stent restenosis. However, the recurrent
restenosis still occurs in some cases. The predictors of recurrent restenosis are
incompletely understood. The aim of this study was to evaluate the predictors of
recurrent restenosis in patients treated with PCB for in-stent restenosis.
Methods: Data of the patients treated with PCB (SeQuent please) for in-stent reste-
nosis between 2008 and 2012 were collected. A total of 453 patients with 539 lesions
[(bare-metal stent restenosis (BMS-ISR); 113 lesions, drug-eluting stent restenosis
(DES-ISR); 426 lesions)] were analyzed in this study. Follow-up angiogram was
obtained in 476 lesions 6 months after procedure (follow-up rate: 88.3%). We eval-
uated the predictors of recurrent restenosis in patients treated with PCB for in-stent
restenosis.
Results: Recurrent restenosis occurred in 13 lesions (13.3%) of BMS-ISR and 79
lesions (20.9%) of DES-ISR. Target lesion revascularization was performed to 7 le-
sions (7.1%) of BMS-ISR and 54 lesions (14.3%) of DES-ISR. Late lumen loss was
lower in BMS-ISR than in DES-ISR (0.17 +/- 0.50 mm vs. 0.29 +/- 0.57 mm,
p¼0.04). Previous stent size  2.5mm (odds ratio [OR]: 1.84, 95% conﬁdence interval
[CI]: 1.13 to 3.02, p¼0.01), total occlusion lesions (OR: 2.74, CI: 1.15 to 6.36,
p¼0.02), and percentage diameter stenosis after procedure > 35% (OR: 1.72, CI: 1.03
to 2.85, p¼0.04) were independent predictors of recurrent restenosis.
Conclusions: Small vessels, total occlusion lesions, and residual stenosis >35% were
the predictors of recurrent restenosis in patients treated with PCB for in-stent
restenosis.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/DrTCT-279
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Background: In randomized clinical trials, efﬁcacy and safety of paclitaxel-coated
balloon (PCB) angioplasty for the treatment of bare-metal stent (BMS) and drug-
eluting stent (DES) restenosis was demonstrated. However there is few data if
different PCBs perform equally. This study aims to evaluate the long-term efﬁcacy of
two second-generation PCBs in treating coronary in-stent restenosis (ISR).
Methods: Between October 2010 and February 2012, all consecutive patients with ISR
lesions treated with the SeQuent Please PCB (B. Braun,Melsungen, Germany) or with
theDIORPCB (Eurocor GmbH,Bonn,Germany) at our institutionwere prospectively
included. Patients were followed up for 24 months by clinical observation. The primary
endpoint was the clinically driven target lesion revascularization (TLR) rate at 24
months. The secondary endpoint was the rate of major adverse cardiac events (MACEs),
deﬁned as a composite of cardiac death, myocardial infarction, and TLR at 24 months.
Results: 65 patients with 74 ISR lesions were included. 43 ISR lesions (21 BMS, 22
DES) were treated with the SeQuent Please PCB and 31 (11 BMS, 20 DES) with the
DIOR PCB. Baseline clinical, lesion characteristics and procedural data did not
signiﬁcantly differ between two groups. The TLR rate was signiﬁcantly lower in patients
with the SeQuent Please PCB compared with the DIOR PCB (4.7% vs. 22. 6%, p¼
0.03) at 24 months. The number of patients who suffered a MACE was not statistically
different across study groups, but a strong trend towards better clinical outcome was
discovered in the SeQuent Please PCB group (9.3 % vs. 25.8%, p¼0.058).
Conclusions: This real-world practice registry suggests that there are signiﬁcant differ-
ences in terms of TLR between two clinically available PCBs. The SeQuent Please PCB
demonstrated lower TLR rate compared to the DIOR PCB at 24 months follow-up.
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Background: The treatment of coronary in–stent restenosis (ISR) is challenging.
Drug–eluting stent (DES) implantation for ISR has not showed satisfactory results.
Drug–coated balloon (DCB) has been recently compared with DES for ISR treatment
with controversial results.
Methods: A systematic literature review in Pubmed/MEDLINE, Embase, Scopus, ISI
Web of Science, ScienceDirect electronic databases was performed to identify ran-
domized controlled trials (RCTs) comparing DCB with DES in ISR. No ﬁlters or
language restrictions were imposed. The keywords used were the following: “drug
coated balloon”, “drug eluting balloon”, and “paclitaxel eluting balloon”. The endpoint
was a composite of major adverse cardiovascular events (MACE) at 12 months, re-
ported as pooled risk ratio (RR) with 95% conﬁdence interval (CI). A DerSimonian-
Laird random-effects model was used. Heterogeneity was graded with I2 statistic.
Results: A total of 4 randomized controlled trials comparingDCB andDESwere identiﬁed.
Thepooled analysis showed a similar risk ofMACEat 12months between the two treatments
(RR 1.04, 95%CI 0.73–1.47, p¼0.83). The heterogeneity degreewas low (8.7%). However,
differently from the others, PEPCAD II trial exhibited a clear risk reduction with DCB (RR
0.45). To exclude a signiﬁcant impact of this trial on pooled RR, a sequential one study
removal was performed. Excluding PEPCAD II the pooled RR tended toward a modest RR
reduction associated with DES (RR 1.17, 95% CI 0.82–1.67, p¼0.38).Conclusions: DES implantation for ISR compared with DCB might lead to a modest
reduction in the risk of MACE at 12 months.ug-Eluting Balloons and Local Drug Delivery B81
